A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma.

Bumma N, Lee HC, Richter J, Hoffman JE, Zonder JA, Fillbrunn M, Garcia-Horton V, Zhou ZY, Xu Y, Burnett H, Harnett J, Inocencio TJ, Little M, Knorr K, Kroog GS, Xu W, Ma Q, Jagannath S

Open source

DOI: 10.1080/03007995.2026.2686032
Published: 2026 May
Container: Current medical research and opinion
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/03007995.2026.2686032,
  title = {A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma.},
  author = {Bumma N and Lee HC and Richter J and Hoffman JE and Zonder JA and Fillbrunn M and Garcia-Horton V and Zhou ZY and Xu Y and Burnett H and Harnett J and Inocencio TJ and Little M and Knorr K and Kroog GS and Xu W and Ma Q and Jagannath S},
  year = {2026},
  journal = {Current medical research and opinion},
  doi = {10.1080/03007995.2026.2686032},
  url = {https://doi.org/10.1080/03007995.2026.2686032}
}

RIS

TY  - JOUR
TI  - A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma.
AU  - Bumma N
AU  - Lee HC
AU  - Richter J
AU  - Hoffman JE
AU  - Zonder JA
AU  - Fillbrunn M
AU  - Garcia-Horton V
AU  - Zhou ZY
AU  - Xu Y
AU  - Burnett H
AU  - Harnett J
AU  - Inocencio TJ
AU  - Little M
AU  - Knorr K
AU  - Kroog GS
AU  - Xu W
AU  - Ma Q
AU  - Jagannath S
PY  - 2026
JO  - Current medical research and opinion
DO  - 10.1080/03007995.2026.2686032
UR  - https://doi.org/10.1080/03007995.2026.2686032
ER  -

APA

N, B., HC, L., J, R., JE, H., JA, Z., M, F., V, G., ZY, Z., Y, X., H, B., J, H., TJ, I., M, L., K, K., GS, K., W, X., Q, M., & S, J. (2026). A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma.. Current medical research and opinion. https://doi.org/10.1080/03007995.2026.2686032

Source records

pubmed · retrieved 2026-09-25T19:38:28.159Z